Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Geron Corporation (GERN : NSDQ)
 
 • Company Description   
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Number of Employees: 72

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.41 Daily Weekly Monthly
20 Day Moving Average: 2,210,399 shares
Shares Outstanding: 377.45 (millions)
Market Capitalization: $532.20 (millions)
Beta: 0.99
52 Week High: $2.23
52 Week Low: $0.99
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 9.57%
12 Week 35.58% 47.11%
Year To Date 15.57% 37.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
919 EAST HILLSDALE BOULEVARD SUITE 250
-
FOSTER CITY,CA 94404
USA
ph: 650-473-7700
fax: 650-473-7750
investor@geron.com http://www.geron.com
 
 • General Corporate Information   
Officers
John A. Scarlett - President; Chief Executive Officer and Chairman
Olivia Bloom - Executive Vice President; Finance; ChiefFinancial
Dawn C. Bir - Director
Karin Eastham - Director
V. Bryan Lawlis - Director

Peer Information
Geron Corporation (CORR.)
Geron Corporation (RSPI)
Geron Corporation (CGXP)
Geron Corporation (BGEN)
Geron Corporation (GTBP)
Geron Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 374163103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 377.45
Most Recent Split Date: (:1)
Beta: 0.99
Market Capitalization: $532.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.68
Price/Cash Flow: -
Price / Sales: 385.93
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 10.00%
Sales Growth
vs. Year Ago Period: -10.22%
vs. Previous Quarter: -88.17%
ROE
03/31/22 - -85.84
12/31/21 - -70.87
09/30/21 - -58.33
ROA
03/31/22 - -52.28
12/31/21 - -48.08
09/30/21 - -42.70
Current Ratio
03/31/22 - 3.77
12/31/21 - 4.11
09/30/21 - 4.66
Quick Ratio
03/31/22 - 3.77
12/31/21 - 4.11
09/30/21 - 4.66
Operating Margin
03/31/22 - -8,584.92
12/31/21 - -8,335.39
09/30/21 - -26,769.73
Net Margin
03/31/22 - -8,584.92
12/31/21 - -8,335.39
09/30/21 - -26,769.73
Pre-Tax Margin
03/31/22 - -8,584.92
12/31/21 - -8,335.39
09/30/21 - -26,769.72
Book Value
03/31/22 - 0.26
12/31/21 - 0.39
09/30/21 - 0.47
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.51
12/31/21 - 0.39
09/30/21 - 0.23
Debt-to-Capital
03/31/22 - 33.98
12/31/21 - 28.27
09/30/21 - 18.62
 

Powered by Zacks Investment Research ©